CoChat

Concerted Activation of ETS Protein ER81 by p160 Coactivators, the Acetyltransferase p300 and the Receptor Tyrosine Kinase HER2/Neu

Open access
Goel, Apollina, Janknecht, Ralf · 2004 · Journal of Biological Chemistry

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Activator of thyroid and retinoic acid receptor (ACTR) is overexpressed in approximately 60% of primary human breast tumors and belongs to the p160 steroid receptor coactivator family. In this study, we identified a novel interaction partner of ACTR, the ETS transcription factor ER81 that is also heavily implicated in mammary tumor formation. ACTR and related p160 family members (steroid receptor coactivator-1 and glucocorticoid receptor-interacting protein-1 (GRIP-1)) augment ER81-mediated transcription. Although ACTR and GRIP-1 can acetylate ER81, this posttranslational modification of ER81 is not required for its stimulation by ACTR or GRIP-1. In addition, ACTR collaborates with the p300 coactivator, a joint interaction partner of ACTR and ER81, to stimulate ER81 function and the ability of p300 to acetylate ER81 is indispensable for this collaboration. Furthermore, the receptor tyrosine kinase HER2/Neu, an oncoprotein particularly found overexpressed in breast tumors, cooperates with both ACTR and p300 to stimulate ER81-mediated transcription. Thus, oncogenic HER2/Neu and ACTR may synergize to orchestrate mammary tumorigenesis through the dysregulation of the transcription factor ER81 and its target genes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m400036200

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1 SRCs stimulate the PEA3 subfamily of transcription factors. A , CV-1 cells were cotransfected with MMP-1 luciferase reporter, CMV-ER812-477 (0.5 𝛍 g), SRC-1 (0.25 𝛍 g), GRIP-1 (0.25 𝛍 g), or ACTR (0.25 𝛍 g) as indicated. The resulting relative luciferase activities are depicted. B , RT-PCR analyses of endogenous MMP-1 mRNA production, and as a control GAPDH , in 293T cells transfected with CMVER812-477 (0.2 𝛍 g), p160 coactivators (0.1 𝛍 g), and p300 (0.1 𝛍 g) as indicated. C , transient transfections of CV-1 cells with MMP-1 luciferase reporter, 0.25 𝛍 g of ACTR, and 0.5 𝛍 g of expression plasmids for ER81, PEA3, ERM, Elk1, Sap1a, or ER71. D , corresponding RT-PCR analyses of 293T cells transfected with 0.1 𝛍 g of ACTR and 0.2 𝛍 g of various ETS protein expression plasmids.
FIG. 1 SRCs stimulate the PEA3 subfamily of transcription factors. A , CV-1 cells were cotransfected with MMP-1 luciferase reporter, CMV-ER812-477 (0.5 𝛍 g), SRC-1 (0.25 𝛍 g), GRIP-1 (0.25 𝛍 g), or ACTR (0.25 𝛍 g) as indicated. The resulting relative luciferase activities are depicted. B , RT-PCR analyses of endogenous MMP-1 mRNA production, and as a control GAPDH , in 293T cells transfected with CMVER812-477 (0.2 𝛍 g), p160 coactivators (0.1 𝛍 g), and p300 (0.1 𝛍 g) as indicated. C , transient transfections of CV-1 cells with MMP-1 luciferase reporter, 0.25 𝛍 g of ACTR, and 0.5 𝛍 g of expression plasmids for ER81, PEA3, ERM, Elk1, Sap1a, or ER71. D , corresponding RT-PCR analyses of 293T cells transfected with 0.1 𝛍 g of ACTR and 0.2 𝛍 g of various ETS protein expression plasmids.CC-BY · From the PDF
FIG. 2 ACTR interacts with ER81. A , coimmunoprecipitation of endogenous ACTR and ER81 in HeLa cells. Immunoprecipitations were performed with anti-ER81, control anti-GAL4, or no antibodies, and ACTR was subsequently detected by anti-ACTR Western blotting. The bottom panels show input levels of ER81 and ACTR. B , GST pull-downs of Myc6-ACTR, HA-CARM1, or HA-PRMT1. Protein binding to GST or GST-ER812-477 was revealed by anti-Myc (ACTR) or anti-HA Western blotting (CARM1 and PRMT1).
FIG. 2 ACTR interacts with ER81. A , coimmunoprecipitation of endogenous ACTR and ER81 in HeLa cells. Immunoprecipitations were performed with anti-ER81, control anti-GAL4, or no antibodies, and ACTR was subsequently detected by anti-ACTR Western blotting. The bottom panels show input levels of ER81 and ACTR. B , GST pull-downs of Myc6-ACTR, HA-CARM1, or HA-PRMT1. Protein binding to GST or GST-ER812-477 was revealed by anti-Myc (ACTR) or anti-HA Western blotting (CARM1 and PRMT1).CC-BY · From the PDF
FIG. 3 Mapping of interaction domains in ACTR and ER81. A , the top panel shows a schematic representation of ACTR. RID , receptorinteracting domain; CID , CBP/p300-interacting domain. The middle panels show anti-FLAG immunoprecipitates of 293T cells transfected with FLAG-tagged ER81 and the indicated Myc-tagged ACTR constructs. Coimmunoprecipitated ACTR molecules were detected by anti-Myc Western blotting. The bottom panels show input levels of the various ACTR truncations. B , the top panel schematically depicts ER81. AD , activation domain; NRD , negative regulatory domain; ETS , DNA binding domain. GST-ER81 fusion proteins were pre-bound to glutathione-agarose and incubated with Myc-tagged ACTR. Bound ACTR was revealed by anti-Myc Western blotting. The bottom panel shows a Coomassie Blue-stained protein gel of GST and the various GST-ER81 proteins utilized.
FIG. 3 Mapping of interaction domains in ACTR and ER81. A , the top panel shows a schematic representation of ACTR. RID , receptorinteracting domain; CID , CBP/p300-interacting domain. The middle panels show anti-FLAG immunoprecipitates of 293T cells transfected with FLAG-tagged ER81 and the indicated Myc-tagged ACTR constructs. Coimmunoprecipitated ACTR molecules were detected by anti-Myc Western blotting. The bottom panels show input levels of the various ACTR truncations. B , the top panel schematically depicts ER81. AD , activation domain; NRD , negative regulatory domain; ETS , DNA binding domain. GST-ER81 fusion proteins were pre-bound to glutathione-agarose and incubated with Myc-tagged ACTR. Bound ACTR was revealed by anti-Myc Western blotting. The bottom panel shows a Coomassie Blue-stained protein gel of GST and the various GST-ER81 proteins utilized.CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
FIG. 7 Collaboration among HER2/Neu, p300, and ACTR in activating ER81. A , MMP-1 luciferase activities in CV-1 cells transiently transfected with CMV-ER812-477 (0.2 𝛍 g), HA-p300 (0.3 𝛍 g), Myc6-ACTR (0.25 𝛍 g), and HER2/Neu-V664E (0.25 𝛍 g). B , RT-PCR analysis of endogenous MMP-1 gene activation was performed using cytosolic RNA from 293T cells transiently transfected with CMVER812-477 (0.2 𝛍 g), p300 (0.1 𝛍 g), ACTR (0.1 𝛍 g), and HER2/Neu-V664E (1 𝛍 g). Expression of GAPDH was evaluated as an internal control.
FIG. 7 Collaboration among HER2/Neu, p300, and ACTR in activating ER81. A , MMP-1 luciferase activities in CV-1 cells transiently transfected with CMV-ER812-477 (0.2 𝛍 g), HA-p300 (0.3 𝛍 g), Myc6-ACTR (0.25 𝛍 g), and HER2/Neu-V664E (0.25 𝛍 g). B , RT-PCR analysis of endogenous MMP-1 gene activation was performed using cytosolic RNA from 293T cells transiently transfected with CMVER812-477 (0.2 𝛍 g), p300 (0.1 𝛍 g), ACTR (0.1 𝛍 g), and HER2/Neu-V664E (1 𝛍 g). Expression of GAPDH was evaluated as an internal control.CC-BY · From the PDF
FIG. 6 HATactivity of p300 contributes to its synergy with ACTR. A , CV-1 cells were transiently transfected with MMP-1 luciferase reporter and 0.5 𝛍 g of CMV-ER812-477, 0.3 𝛍 g of p300, p300 𝚫 HAT, or p300 𝚫 SRC, and 0.25 𝛍 g of Myc6-ACTR as shown. B , a similar comparison between wild-type CMV-ER81 and its K33R/K116R mutant.
FIG. 6 HATactivity of p300 contributes to its synergy with ACTR. A , CV-1 cells were transiently transfected with MMP-1 luciferase reporter and 0.5 𝛍 g of CMV-ER812-477, 0.3 𝛍 g of p300, p300 𝚫 HAT, or p300 𝚫 SRC, and 0.25 𝛍 g of Myc6-ACTR as shown. B , a similar comparison between wild-type CMV-ER81 and its K33R/K116R mutant.CC-BY · From the PDF
Image 8
CC-BY · From the PDF
FIG. 8 Model for how oncogenic HER2/Neu and ACTR contribute to breast cancer formation via ER81 and p300.
FIG. 8 Model for how oncogenic HER2/Neu and ACTR contribute to breast cancer formation via ER81 and p300.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 7

  1. Bautista, S., Valles, H., Walker, R. L., Anzick, S., Zeillinger, R., Meltzer, P., and Theillet, C. (1998) Clin. Cancer Res. 4, 2925-2929
  2. Sakakura, C., Hagiwara, A., Yasuoka, R., Fujita, Y., Nakanishi, M., Masuda, K., Kimura, A., Nakamura, Y., Inazawa, J., Abe, T., and Yamagishi, H. (2000) Int. J. Cancer 89, 217-223 · doi:10.1002/1097-0215(20000520)89:3<217::aid-ijc2>3.0.co;2-6
  3. Trimble, M. S., Xin, J. H., Guy, C. T., Muller, W. J., and Hassell, J. A. (1993) Oncogene 8, 3037-3042
  4. Janknecht, R., and Nordheim, A. (1993) Biochim. Biophys. Acta 1155, 346 -356
  5. Janknecht, R., Ernst, W. H., and Nordheim, A. (1995) Oncogene 10, 1209 -1216
  6. Janknecht, R. (2002) Histol. Histopathol. 17, 657-668
  7. Bouras, T., Southey, M. C., and Venter, D. J. (2001) Cancer Res. 61, 903-907

Cited by

See all 95

Metadata

Authors
Goel, A., & Janknecht, R.
Affiliations
Mayo Clinic (US)
Corresponding author
Janknecht, Ralf
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2004-04
Volume
279
Issue
15
Pages
14909-14916
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2029169609
Cited by
95
References
65
Citations by year
2026: 2 · 2025: 1 · 2023: 9 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2016: 5 · 2015: 2 · 2014: 6 · 2013: 3 · 2012: 6
FWCI
3.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Fraternal Order of Eagles
  • Mayo Foundation for Medical Education and Research
  • National Cancer Institute (R01CA085257, CA085257)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
ER81, ETS transcription factors, ACT-R, p160 coactivators, P300, HER2/neu, protein acetylation, transcriptional activation, breast cancer, mammary carcinogenesis, SRC-1, protein-protein interaction
MeSH terms
p300-CBP-Associated Factor, Acetyltransferases, Animals, Breast Neoplasms, Carrier Proteins, Cell Line, DNA-Binding Proteins, Electrophoresis, Polyacrylamide Gel, Glutathione Transferase, HeLa Cells, Humans, Luciferases, Models, Biological, Nuclear Proteins, Plasmids, Precipitin Tests, Protein Binding, Protein Processing, Post-Translational, Recombinant Fusion Proteins, RNA, Transcription Factors, Transcription, Genetic, RNA-Binding Proteins, Protein Structure, Tertiary, Receptors, Retinoic Acid, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Cell Cycle Proteins, Reverse Transcriptase Polymerase Chain Reaction, Nucleocytoplasmic Transport Proteins, p300-CBP Transcription Factors, Histone Acetyltransferases, Nuclear Receptor Coactivator 2, Nuclear Receptor Coactivator 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.